Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Endocyte Shares Had a Case of Deja Vu

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Endocyte (NASDAQ: ECYT  ) , a biopharmaceutical company focused on developing oncological and inflammatory disease treatments, jumped by double digits -- as much as 13% to be exact -- for the second time in three days after receiving another price target hike by a research firm.

So what: On Monday, R.W. Baird boosted its rating on Endocyte to "outperform" from "neutral" and raised its price target on the company by 44% to $13. Today, Wedbush Securities analyst Gregory Wade boosted his price target on Endocyte to $20 from $16, citing the fact that Wall Street has overlooked the potential for the company's ovarian and lung cancer treatment Vintafolide, which is being licensed out to Merck (NYSE: MRK  ) . Wade estimates that peak sales of the drug -- if approved in the U.S. and Europe -- could reach $500 million domestically and $400 million in Europe.

Now what: I know you've heard this a thousand times before, but keep in mind that analyst actions are rarely long-term drivers of a company's share price, so don't pay them too much credence. However, I can't help but note that I do agree with Wedbush analyst Wade's focus on Vintafolide, which I touched on briefly on Monday. An approval in either the U.S. or EU (or both) would be the most immediate catalyst for Endocyte with everything else coming up a clear second. It's a company that definitely bears watching.

Craving more input? Start by adding Endocyte to your free and personalized watchlist so you can keep up on the latest news with the company.

Keeping your eye on individual companies is good, but keep in mind overall trends, too. What macro trend was Warren Buffett referring to when he said "this is the tapeworm that's eating at American competitiveness"? Find out in our free report: What's Really Eating At America's Competitiveness. You' also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2334907, ~/Articles/ArticleHandler.aspx, 9/29/2016 8:22:14 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 10 hours ago Sponsored by:
DOW 18,339.24 110.94 0.61%
S&P 500 2,171.37 11.44 0.53%
NASD 5,318.55 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/28/2016 4:00 PM
ECYT $3.29 Down -0.01 -0.30%
Endocyte CAPS Rating: ****
MRK $63.30 Up +0.73 +1.17%
Merck and Co. CAPS Rating: ****